We are live on ! Find out more
CINC

CinCor Pharma, Inc. Common Stock
CINC

Delisted

CINC was delisted on the 23rd of February, 2023.

Back to rankings

57 hedge funds and large institutions have $596M invested in CinCor Pharma, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

100% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 12

15% more capital invested

Capital invested by funds: $520M → $596M (+$75.8M)

8% more funds holding

Funds holding: 53 → 57 (+4)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
57
Holders Change
+4
Holders Change %
+7.55%
% of All Funds
0.96%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
9
Increased
24
Reduced
12
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$11.3M
2
DCM
Driehaus Capital Management
Illinois
+$9.33M
3
JP Morgan Chase
JP Morgan Chase
New York
+$3.62M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.38M
5
BlackRock
BlackRock
New York
+$3.18M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$1.74M
2
CCM
CAAS Capital Management
New York
-$1.32M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$751K
4
PHK
Point72 Hong Kong
Hong Kong
-$387K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$334K
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
$105M – – –
5VM
2
5AM Venture Management
California
$81.7M – – –
GA
3
General Atlantic
New York
$77.7M – – –
PA
4
Perceptive Advisors
New York
$43.7M – – –
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$42.7M +$3.38M +176,448 +8%
VP
6
venBio Partners
California
$40.4M +$3.15M +164,329 +8%
BI
7
BVF Inc
California
$31M -$1.74M -90,900 -5%
RI
8
RTW Investments
New York
$26.2M – – –
RSCM
9
Rock Springs Capital Management
Maryland
$19.2M -$191K -10,000 -1%
OFM
10
Omega Fund Management
Massachusetts
$18.2M – – –
SCV
11
Sands Capital Ventures
Virginia
$17.9M – – –
BlackRock
12
BlackRock
New York
$15.9M +$3.18M +166,255 +25%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$12.8M -$751K -39,253 -5%
GPP
14
Great Point Partners
Connecticut
$12.6M +$11.3M +589,530 +740%
Vanguard Group
15
Vanguard Group
Pennsylvania
$11.9M +$217K +11,352 +2%
DCM
16
Driehaus Capital Management
Illinois
$9.18M +$9.33M +487,279 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$4.34M +$414K +21,644 +10%
State Street
18
State Street
Massachusetts
$4.21M +$1.9M +99,371 +80%
JP Morgan Chase
19
JP Morgan Chase
New York
$3.66M +$3.62M +188,904 +3,472%
AG
20
Artal Group
Luxembourg
$2.58M +$2.62M +137,010 New
Northern Trust
21
Northern Trust
Illinois
$2.15M +$275K +14,345 +14%
Charles Schwab
22
Charles Schwab
California
$1.72M +$45.8K +2,394 +3%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$1.61M +$58.7K +3,065 +4%
TD Asset Management
24
TD Asset Management
Ontario, Canada
$979K – – –
N
25
Nuveen
North Carolina
$973K +$678K +35,424 +219%
1
2 3

CINC Hedge Fund Activity: Q2 2022 in Review

57 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q2 2022, worth a combined $596M — up 15% from $520M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CINC positions and 4 closed out — a net gain of 5 holders — while 24 added to existing stakes and 12 trimmed.

The largest buyer was Great Point Partners, adding an estimated $11.3M. The largest seller was BVF Inc, cutting an estimated $1.74M.

  • 57 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q2 2022, up from 53 in Q1 2022.
  • Funds reported $596M of CinCor Pharma, Inc. Common Stock stock for Q2 2022, up 15% quarter-over-quarter.
  • 9 funds opened new CinCor Pharma, Inc. Common Stock positions in Q2 2022 and 4 closed out, a net change of +5 holders.
  • The largest CinCor Pharma, Inc. Common Stock buyer in Q2 2022 was Great Point Partners, an estimated $11.3M added.
  • The largest CinCor Pharma, Inc. Common Stock seller in Q2 2022 was BVF Inc, an estimated $1.74M sold.

Based on aggregated 13F filings for Q2 2022.